Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

PROCHLORPERAZINE

All products: general benefit

Other products in the same Health Canada class (N05A, N05AB) — coverage varies; not interchangeable

  • Fluphenazine (Moditen HCL): general benefit, Not a benefit
  • Perphenazine (Trilafon): general benefit, Not a benefit
  • Trifluoperazine (Trifluoperazine): general benefit, Not a benefit
  • Aripiprazole (Abilify Asimtufii): general benefit
  • Asenapine (Saphris): general benefit
  • Brexpiprazole (Rexulti): general benefit

18 more in the class list below

Prochlorazine · DIN 00886432 · 10mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Prochlorazine · DIN 00886432 Manufacturer: A A Pharma Inc.; listing date 2001-06-07 Health Canada: Marketed since 2013-04-30 · brand PROCHLORAZINE · ATC N05AB04 PROCHLORPERAZINE, N05AB04 PROCHLORPERAZINE · form Tablet · route Oral · ingredients PROCHLORPERAZINE (PROCHLORPERAZINE MALEATE) 10 MG · company Aa pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Prochlorazine: Formulary list price $0.2025/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2025 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=45324 · Verify on the e-Formulary ↗ (DIN 00886432)

Source record
DIN 00886432: Prochlorazine Raw flags: sec3=Y Item: 281608062; group id 505; item number 1315; lccId None; manufacturer id AAP Source form: Tab; strength: 10mg Recorded listing: General benefit Source prices (unrounded): $0.2025; ministry $0.2025 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00886432 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=45324
Interchangeable products
Stemetil · DIN 01927760 · not recorded
Shortage status: resolved shortage (ended 2025-11-04); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00886432
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (28:16:08 Tranquilizers) and how they are covered

Matched class: 28:16:08 Tranquilizers

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ARIPIPRAZOLE, ASENAPINE, BREXPIPRAZOLE, CARIPRAZINE, FLUPENTIXOL DECANOATE, FLUPENTIXOL DIHYDROCHLORIDE, PALIPERIDONE, PALIPERIDONE PALMITATE, PERICYAZINE, PIMOZIDE, ZIPRASIDONE HCL MONOHYDRATE, ZUCLOPENTHIXOL DECANOATE, ZUCLOPENTHIXOL DIHYDROCHLORIDE Some products covered without a code (check the product listing): ALPRAZOLAM, BROMAZEPAM, CHLORDIAZEPOXIDE, CHLORPROMAZINE, CLORAZEPATE DIPOTASSIUM, DIAZEPAM, FLUPHENAZINE HCL, HALOPERIDOL, HALOPERIDOL DECANOATE, LORAZEPAM, LOXAPINE SUCCINATE, LURASIDONE HYDROCHLORIDE, OLANZAPINE, OXAZEPAM, PERPHENAZINE, QUETIAPINE, RISPERIDONE, TRIFLUOPERAZINE 28:16:08 Tranquilizers

FLUPHENAZINE HCL

· 6 products · Listed, not a benefit (3), General benefit (3) · strengths: 1mg, 2mg, 5mg · Tab

PERPHENAZINE

· 8 products · Listed, not a benefit (4), General benefit (4) · strengths: 2mg, 4mg, 8mg, 16mg · Tab

TRIFLUOPERAZINE

· 8 products · General benefit (4), Listed, not a benefit (4) · strengths: 1mg, 2mg, 5mg, 10mg · Tab

ARIPIPRAZOLE

· 70 products · General benefit · strengths: 720mg/2.4mL, 960mg/3.2mL, 300mg/Vial, 400mg/Vial, 2mg, 5mg, 10mg, 15mg, 20mg, 30mg · Inj Sol-Pref Syr, Prolong-Rel Inj Pd-Vial Pk, Tab

ASENAPINE

· 2 products · General benefit · strengths: 5mg, 10mg · SL Tab

BREXPIPRAZOLE

· 6 products · General benefit · strengths: 0.25mg, 0.5mg, 1mg, 2mg, 3mg, 4mg · Tab

CARIPRAZINE

· 4 products · General benefit · strengths: 1.5mg, 3mg, 4.5mg, 6mg · Cap

CHLORPROMAZINE

· 6 products · General benefit (3), Listed, not a benefit (3) · strengths: 25mg, 50mg, 100mg · Tab

FLUPENTIXOL DECANOATE

· 2 products · General benefit · strengths: 20mg/mL, 100mg/mL · Inj Sol-1mL Amp Pk

FLUPENTIXOL DIHYDROCHLORIDE

· 2 products · General benefit · strengths: 0.5mg, 3mg · Tab

HALOPERIDOL

· 14 products · Listed, not a benefit (7), General benefit (7) · strengths: 5mg/mL, 0.5mg, 1mg, 2mg, 5mg, 10mg, 20mg · Inj Sol-1mL Pk, Tab

LOXAPINE SUCCINATE

· 8 products · Listed, not a benefit (4), General benefit (4) · strengths: 5mg, 10mg, 25mg, 50mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 28:16:08 and 21 more
Full class listing Related classes: 28:08:04 Nonsteroidal Anti-Inflammatory Agents, 28:08:08 Opiate Agonists, 28:08:12 Opiate Partial Agonists, 28:08:92 Miscellaneous Analgesics and Antipyretics, 28:16:04 Antidepressants, 28:16:12 Other Psychotropics, 28:36:08 Anticholinergic Agents, 28:36:20 Dopamine Receptor Agonists Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: manifestations of psychotic disorders
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. No displayed matched alternative is a general benefit. FLUPHENAZINE HCL · Listed, not a benefit (3), General benefit (3) 1 INDICATIONS FLUPHENAZINE (fluphenazine hydrochloride) is indicated for: • Management of manifestations of psychotic disorders. PM: https://pdf.hres.ca/dpd_pm/00069653.PDF; date DEC 31, 1977; DIN 00405345; fetched 2026-09-10 Product monograph PERPHENAZINE · Listed, not a benefit (4), General benefit (4) Indications PERPHENAZINE (perphenazine tablets) is indicated for: • Management of manifestations of psychotic disorders. PM: https://pdf.hres.ca/dpd_pm/00084763.PDF; date May 15, 2026; DIN 00335096; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
1. Indications PROCHLORAZINE (Prochlorperazine Maleate Tablets) is indicated for: • the management of manifestations of psychotic disorders such as agitation, confusion, delusion, tension and anxiety. • controlling nausea and vomiting due to stimulation of the chemoreceptor trigger zone. In selected patients, prochlorperazine may be of value for the relief of excessive anxiety, accompanied by severe tension and agitation, associated with psychoneurotic or somatic conditions. 1.1. Pediatrics Pediatrics (> 2 years and < 18 years of age): See 4.2. Recommended Dose and Dosage Adjustment and 7.1.3. Pediatrics. Occasionally the patient may react to the drug with signs of restlessness and excitement; if this occurs, treatment should be discontinued. Acute febrile illness or dehydration: In such patients, the drug should be used under close supervision and at low doses. Pediatrics (< 2 years of age): Do not administer to children under 2 years of age unless potentially lifesaving. Do not administer to children under 9 kg of body weight. 1.2. Geriatrics Geriatrics (> 65 years of age): Evidence from clinical studies and experience suggests that use in the geriatric population i… https://pdf.hres.ca/dpd_pm/00082835.PDF PM date: 2025-12-15 Source product: PROCHLORAZINE; DIN 00886432; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.